This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Navigant Life Sciences Consultant Recognized As A “Rising Star”

Today, Navigant announced that James Dolan, PhD, Associate Director on the Firm’s Life Sciences Strategy team, appears on Consulting Magazine’s list of " Rising Stars of the Profession," which recognizes outstanding talent under the age of 35.

Dolan was selected because of his vast contributions to the Life Sciences division within Navigant’s Healthcare practice and for his passion for driving innovation throughout the Firm and on behalf of clients.

“We’re thrilled to see James on the list of Rising Stars in the industry,” stated Eduardo Schur, Managing Director in the Healthcare practice and global leader of Navigant’s Life Sciences Strategy team. “The recognition by Consulting Magazine affirms what we have long believed about James’ significant contributions – he provides strategic thinking rooted in deep clinical expertise to his clients, adding a spark of innovation and perspective that is incredibly valuable.”

Dolan was among the more than 200 nominees considered by Consulting Magazine. During his five year tenure with Navigant, Dolan has provided consulting services in the areas of immunology and autoimmune disease, oncology, cardiovascular disease, neuroscience, respiratory disease and diabetes. In addition to his consulting work, Dolan is a strategic advisor to the Firm’s Innovation Development Council, providing best practice insight and programmatic direction in support of ideation to drive Firm growth and broaden the Firm’s portfolio.

“It is both humbling and inspiring to be recognized with this award at such an early stage of my career,” said Dolan. “I am further energized by the recognition of my leadership that I’ve earned from practice and executive management. I’m excited to being a part of a growing Life Sciences business and the growth trajectory that Navigant is on, and I am looking forward to continuing to realize success on behalf of my clients and the Firm for a long time ahead.”

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.99 -0.02%
FB $99.54 -0.21%
GOOG $678.11 -0.68%
TSLA $148.25 0.18%
YHOO $26.82 -0.85%


Chart of I:DJI
DOW 16,014.38 -12.67 -0.08%
S&P 500 1,852.21 -1.23 -0.07%
NASDAQ 4,268.7630 -14.99 -0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs